ICO International Coal Grp.

EDISON EQUITY RESEARCH: ICO THERAPEUTICS - MOVING FORWARD WITH ORALAMPB

iCo is deploying C$0.7m in grant funding to move ahead with preclinical development of its proprietary oral formulation of well-established anti-fungal amphotericin B (AmpB). OralAmpB holds potential promise in HIV reservoir treatment, as well as more conventional anti-fungal and parasitic diseases, with a Phase Ia trial expected to start in Q116.

iCo Therapeutics is a Canadian biotech company that in-licenses novel therapeutics. OralAmpB, a proprietary lipid-encapsulated form of antifungal amphotericin B, is in preclinical development. iCo holds rights to iCo-007 and ophthalmic indication rights to bertilimumab (iCo-008).

To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/ico-therapeutics5

Click here to view all of Edison Investment Research’s published reports